Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium - Wikidata - wikimedia - TriplyDB

Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium

Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium

http://www.wikidata.org/entity/Q30439109

about

Improved endpoints for cancer immunotherapy trials Cancer vaccines Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers.Shipping blood to a central laboratory in multicenter clinical trials: effect of ambient temperature on specimen temperature, and effects of temperature on mononuclear cell yield, viability and immunologic function.Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond.Data analysis as a source of variability of the HLA-peptide multimer assay: from manual gating to automated recognition of cell clusters.Modeling flow cytometry data for cancer vaccine immune monitoring.Serum is not required for ex vivo IFN-gamma ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding Program.Performance of serum-supplemented and serum-free media in IFNgamma Elispot Assays for human T cells.An integrative paradigm to impart quality to correlative science.Identification of new MUC1 epitopes using HLA-transgenic animals: implication for immunomonitoring.Utilization of serologic assays to support efficacy of vaccines in nonclinical and clinical trials: meeting at the crossroads New approaches to design HIV-1 T-cell vaccines The immuno-oncology framework: Enabling a new era of cancer therapy.Chagasic patients are able to respond against a viral antigen from influenza virus.Harmonisation of short-term in vitro culture for the expansion of antigen-specific CD8(+) T cells with detection by ELISPOT and HLA-multimer staining Quality assurance of intracellular cytokine staining assays: analysis of multiple rounds of proficiency testing.Optimization of a highly standardized carboxyfluorescein succinimidyl ester flow cytometry panel and gating strategy design using discriminative information measure evaluation.Defining the critical hurdles in cancer immunotherapy.Interrogating the repertoire: broadening the scope of peptide-MHC multimer analysis A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multipeptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma Developing an effective breast cancer vaccine.Colorectal cancer vaccines in clinical trials.Harmonization of immune biomarker assays for clinical studies.Immunological Monitoring to Rationally Guide AAV Gene Therapy.Immune monitoring in cancer vaccine clinical trials: critical issues of functional flow cytometry-based assays.Immune biomarkers: how well do they serve prognosis in human cancers?Validation of immunomonitoring methods for application in clinical studies: The HLA-peptide multimer staining assay.Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study.Soluble MHC-peptide complexes: tools for the monitoring of T cell responses in clinical trials and basic research.Cryopreservation of MHC multimers: Recommendations for quality assurance in detection of antigen specific T cells.A critical assessment for the value of markers to gate-out undesired events in HLA-peptide multimer staining protocols.Structured reporting of T cell assay results.Enumeration of WT1-specific CD8(+) T cells for clinical application using an MHC Streptamer based no-wash single-platform flow-cytometric assay.Evolution of end points for cancer immunotherapy trials.Enzyme-Linked Immunosorbent Spot Assay for the Detection of Wilms' Tumor 1-Specific T Cells Induced by Dendritic Cell Vaccination.Extensive major histocompatibility complex class I binding promiscuity for Mycobacterium tuberculosis TB10.4 peptides and immune dominance of human leucocyte antigen (HLA)-B*0702 and HLA-B*0801 alleles in TB10.4 CD8 T-cell responses

P2860

Q24603112-855513D6-BA71-4277-B798-88C78B556043 Q27024438-2C053A3C-61D9-4864-892F-01EC25C04396 Q28075719-2534663B-ED1A-4625-9AAD-167045D055B9 Q28744503-D9F3DEF3-4506-4AB8-B121-6CFCCC2F9E2E Q30432896-6EB42E7E-637D-4BC8-9B87-AEF3C4C65C2C Q30432926-609C660B-0918-4BB6-91FC-F12D34E8B712 Q30927297-F63B2578-7B08-4D94-AF31-AA9605D04803 Q33610175-6D060C33-A6C0-4BEB-B73D-ECAAA1712870 Q33619141-AF2F86F2-ECB6-443B-B251-2D41BF3E6326 Q33619191-079D1377-019F-4620-B643-A3B8A80D53D8 Q33765942-9837E313-EA92-4A1E-BD37-3C69DC3E7456 Q33876878-38F3E990-2539-4F2D-B39B-EFCE609B787E Q33916408-40916C4C-4A14-43AB-868C-9E0E943DD52B Q34274849-59C335FD-EF3F-4E3F-A576-49E9038E77B1 Q34284462-008CB8C4-F32A-4EAD-A779-6080AC134021 Q34392873-5BA1FDBC-0F5B-4743-B338-FF5E024BF10E Q34402469-1C8DCCE0-2F88-483E-A202-B0D3E370FA85 Q34414321-050EAE66-957A-4170-8BB8-F98AA2534E36 Q34588865-0FEA34D2-0771-41D9-B642-712135A54B5E Q35916968-AC5927DE-C708-4393-8DA6-3C32DD233B9C Q36975877-34CB30EE-B3CE-4917-B6AA-B5A701B76748 Q37262109-D5CD9E73-21E1-4E7B-AA70-3E6B5BD71F7B Q37776145-681A7E2A-C093-475C-A7D7-81A3BDFA20A1 Q37892600-D9E31B9A-DF85-4BDF-96D5-0634A13932FE Q37954593-6243149A-01C3-40F7-89BF-51F73D6B5431 Q38142098-9AA53E94-ABC4-4677-B83E-4B86145029B3 Q38160232-D392D7E5-28ED-4561-BBFF-7D6CCC79ECFB Q38262757-316514A0-70C8-46EC-92FF-70E5A9D52E62 Q39641905-AE1B4F24-5782-4C37-84F9-C501AD78401C Q40148008-6F563919-A200-4962-B175-089F5F435EE7 Q42017582-53B5AC1A-E874-4E6D-BEFE-E919B1BF1BBF Q42184036-8516C6E7-BB07-4C20-B44B-30333DEEA5F9 Q42851663-D26A20E1-8A88-4B7E-A39D-119DB7373F75 Q43081521-B3051FA7-AA99-40EB-AE71-6FA8CB61A330 Q48644166-A7C2CBFF-BB71-4066-B485-4E0A1F04D26B Q50916927-E40095E1-5E90-4C4C-B431-4929EAE5FE01 Q53730546-80A202E3-470D-4511-9DB5-28705449BADD Q57209233-E7EEF6A6-5794-400A-A2D4-B4A72834D441

P2860

Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium

http://www.wikidata.org/entity/Q30439109

description

2009 nî lūn-bûn

@nan

2009 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մարտին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Harmonization guidelines for H ...... the Cancer Vaccine Consortium

@ast

Harmonization guidelines for H ...... the Cancer Vaccine Consortium

@en

type

label

Harmonization guidelines for H ...... the Cancer Vaccine Consortium

@ast

Harmonization guidelines for H ...... the Cancer Vaccine Consortium

@en

prefLabel

Harmonization guidelines for H ...... the Cancer Vaccine Consortium

@ast

Harmonization guidelines for H ...... the Cancer Vaccine Consortium

@en

P1433

Q30439109-46EE7C29-C055-47BE-8633-1E71A9E138D1

P1476

Q30439109-6EF95FE5-02E5-4C60-911B-4F64EDC25096

P2093

Q30439109-319BA4F5-F61C-43C5-BB5F-BCDD5092894C

Q30439109-447F8827-14C1-4B0E-8657-F6BCD84B060C

Q30439109-69623672-64C2-4BAD-9BEA-9DA39433330C

Q30439109-7287140D-3360-450E-A8FB-90208BBE1160

Q30439109-89CD2B9E-5F44-48E7-A13C-52338AC171D4

Q30439109-9C32F481-AE99-4382-9BD6-2D3395F2E6AD

Q30439109-B492620D-056D-46B0-82EE-94CED8A0B21E

Q30439109-BFC48FC4-8438-451A-A89A-29C3B7529B0B

Q30439109-CE46087A-F93A-4541-B63F-14AE9EC1F66C

Q30439109-DAE494DC-5F53-4320-88EB-202BE1EF792F

P2860

Q30439109-0DFC5F4F-2875-4FDE-8E22-3D55C2F5F341

Q30439109-1285C964-4A67-4B2F-8E61-AFF6F1FB5DF1

Q30439109-131579C4-7401-4955-951F-245D8AAFAAE5

Q30439109-250A12E7-855F-495B-8682-DA5603983DEC

Q30439109-33B16617-9D4F-4F7A-BD31-426487EEC8D5

Q30439109-34E99374-7CD8-4F24-AADC-ADB4DCE6B5D5

Q30439109-3DC07597-9BF8-4B35-8BF5-734EC3F273DF

Q30439109-3F33BCC1-6569-48AB-9FD6-EEC6DA4BE3B4

Q30439109-4294CBDF-ECDD-46A3-B0ED-AFB06DBAD4F6

Q30439109-4FD06BFC-C3F7-4817-938C-25C10039D5B2

P2888

Q30439109-4C19CB0B-6355-4ECA-A659-80282686CF2F

P304

Q30439109-53FB31A8-334C-4020-B33F-FCFF317FB597

P31

Q30439109-9F94DF69-7F9D-4B0A-9D78-BD7556D59672

P356

Q30439109-8855FC7B-A3F6-422E-95E2-011E4BCAA457

P433

Q30439109-EF6A6167-333F-4321-865B-50C133D6DE99

P478

Q30439109-17A9547E-ED20-4A40-A2F9-42AAB5F159E6

P50

Q30439109-8710FC85-1A54-4A5C-804A-9F4C4A8BE2EC

P577

Q30439109-4CEFB14A-DB03-4BB7-82CA-C3DA926AA0A0

P5875

Q30439109-5E8BD806-FFFB-457E-9985-EE87C268F501

P6179

Q30439109-E7BD70F7-F00F-439E-A9E2-2542B7E409BA

P698

Q30439109-77BAE83A-88D4-4253-984B-3CAD9E40FB65

P932

Q30439109-E05CA4A6-7D81-495A-9DB9-C6D81DC185A0

P356

S00262-009-0681-Z

P1433

Cancer Immunology, Immunotherapy

P1476

Harmonization guidelines for H ...... the Cancer Vaccine Consortium

@en

P2093

Axel Hoos

http://www.w3.org/2001/XMLSchema#string

Cedrik Michael Britten

http://www.w3.org/2001/XMLSchema#string

HLA-peptide Multimer Proficiency Panel of the CVC-CRI Immune Assay Working Group

http://www.w3.org/2001/XMLSchema#string

Holden Maecker

http://www.w3.org/2001/XMLSchema#string

Leah Ben-Porat

http://www.w3.org/2001/XMLSchema#string

Lloyd Old

http://www.w3.org/2001/XMLSchema#string

Michael Kalos

http://www.w3.org/2001/XMLSchema#string

Michael Pride

http://www.w3.org/2001/XMLSchema#string

Pedro Romero

http://www.w3.org/2001/XMLSchema#string

Sylvia Janetzki

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer immunotherapy: moving beyond current vaccines

Standardization of cytokine flow cytometry assays

Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major

Breast cancer vaccines: a clinical reality or fairy tale?

Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI)

Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen

Precision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides.

Statistical mixture modeling for cell subtype identification in flow cytometry

Evaluation of the modified ELISPOT assay for gamma interferon production in cancer patients receiving antitumor vaccines.

A clinical development paradigm for cancer vaccines and related biologics.

P2888

s00262-009-0681-z

P304

1701-1713

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00262-009-0681-Z

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

58

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-03-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24175791

http://www.w3.org/2001/XMLSchema#string

P6179

1021446896

http://www.w3.org/2001/XMLSchema#string

P698

19259668

http://www.w3.org/2001/XMLSchema#string

P932

2714899

http://www.w3.org/2001/XMLSchema#string